Table 5.
The Chance of Liver-Type Fatty Acid-Binding Protein ≥5.14 μg/g Creatinine—Multivariate Logistic Regression
| ORa | 95% CI | p | |
|---|---|---|---|
| Age | 1.04 | 0.94–1.16 | >0.05 |
| CD4 lymphocytes (cells/μl) | 1.28 | 0.91–1.81 | >0.05 |
| HIV viremia (copies/ml) | 0.63 | 0.05–8.34 | >0.05 |
| Anti-HCV | 5.34 | 0.60–47.60 | >0.5 |
| Years of treatment | 0.83 | 0.64–1.08 | >0.05 |
| Years on present treatment scheme | 1.17 | 0.72–1.92 | >0.05 |
| PIs/NNRTI | 0.83 | 0.12–5.97 | >0.05 |
| eGFR | 0.52 | 0.10–3.37 | >0.05 |
| Weight (kg) | 0.93 | 0.86–0.99 | 0.039 |
a
Odds ratio (OR) adjusted for all variables used in this model.
According to this analysis weight was the only variable of a statistical significance with respect to the occurrence of L-FABP≥5.14 μg/g creatinine.
HCV, hepatitis C virus; PIs, protease inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitor; eGFR (estimated glomerular filtration rate; MDRD formula).